Physician profile
Jordan Stern
NPI 1437182375
$12,491.78
in general payments reported to CMS, 2019-2025
19 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $216 · 2021: $131 · 2022: $10K · 2023: $418 · 2024: $506 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $9,887.48 | 2022 | |
| Jazz Pharmaceuticals INC. | $564.11 | 2021-2024 | |
| W. L. Gore & Associates, INC. | $274.38 | 2019-2020 | |
| Boston Scientific Corporation | $232.87 | 2024-2025 | Enroute Transcarotid Neuroprotection System |
| Harmony Biosciences LLC | $231.60 | 2021-2022 | |
| Medtronic, INC. | $186.94 | 2022 | |
| Endologix LLC | $162.17 | 2019 | |
| Inspire Medical Systems, INC. | $152.83 | 2023 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $149.99 | 2025 | Lumryz |
| Idorsia Pharmaceuticals US INC | $143.67 | 2023 | Quviviq |
| Bard Peripheral Vascular, INC. | $120.62 | 2024 | Rotarexs 6 F X 135 Cm |
| Axsome Therapeutics, INC. | $105.68 | 2025 | Sunosi |
| Kerecis Limited | $91.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Mimedx Group, INC. | $54.24 | 2024-2025 | |
| Organogenesis INC. | $37.58 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $27.42 | 2019 | |
| Access Pro Medical, LLC | $24.81 | 2025 | Matriderm |
| Somnomed INC. | $23.95 | 2024 | |
| Optinose US, INC. | $20.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.